% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • tepper_mark tepper_mark Apr 17, 2010 6:04 PM Flag


    When this gets approved, I believe that Celldex will get a big bump up. This will only validate the potential in this new era of vacines....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Tepper, you are correct.

      Provenge, which is poised to become the first active cellular immunotherapy approved by the Agency to harness a patient's own immune system in the fight against the disease.

      Celldex is an innovative biotechnology company focused on the discovery, development and commercialization of targeted immunotherapies. Our core focus includes the use of tumor-specific targets and human monoclonal antibodies as precision delivered therapeutic agents for the treatment of cancer, infectious and inflammatory diseases through our novel “targeted immunization” approach. We have developed our Antigen Presenting Cell Targeting Technology (APC Targeting Technology™) that utilizes proprietary human monoclonal antibodies to directly target specialized types of immune system cells known as antigen presenting cells or APCs - particularly dendritic cells. We are using this technology approach to build a substantial pipeline of clinical development candidates that will address significant gaps in the treatment of many specific cancers as well as within our growing activities in infectious and inflammatory diseases.
      The collaboration will encompass the development of next-generation immunotherapies using Celldex’s proprietary APC targeting monoclonal antibodies and the Ludwig TAAs. These development candidates will be available to LICR for evaluation within the Cancer Vaccine Collaborative (CVC) worldwide clinical research network, a collaboration between the LICR and the leading cancer charity, the New York-based Cancer Research Institute.

      “The Celldex technology is a novel approach to inducing a patient’s immune system to fight cancer,” said Jonathan C.A. Skipper, Ph.D., Executive Director for Intellectual Property & Technology Licensing at the Ludwig Institute. “This system has the potential to deliver TAAs precisely to the right cells, in contrast to other TAA delivery technologies. The CVC is very much looking forward to exploring this promising TAA delivery approach in its early-phase clinic trials.”

3.18-0.05(-1.55%)4:00 PMEDT